Printer Friendly

CYGNUS BOARD OF DIRECTORS NAMES ANTHONY CHAN CFO

 REDWOOD CITY, Calif., June 10 /PRNewswire/ -- At the annual shareholders' meeting, held on June 8, the board of directors of Cygnus Therapeutic Systems (NASDAQ: CYGN), a transdermal drug delivery company, announced the appointment of Anthony S. S. Chan, CPA, as chief financial officer. Chan has served as corporate controller of Cygnus since June 1992, under Shirley Liu Clayton, who is leaving Cygnus to become chief financial officer of Topometrix Inc.
 "Anthony has been closely involved with our financial planning and management over the year since he joined Cygnus," said Greg Lawless, president and chief executive officer. "While we are sorry to see Shirley leave, Anthony's succession to CFO will make this an exceptionally smooth transition. He will help us bring Cygnus toward our next level of growth."
 Chan has over 20 years experience in all areas of financing, financial planning and administration in worldwide high-technology companies. He has been heavily involved in domestic and international operations for both start-up and established companies, including Memorex-Telex, Fairchild Semiconductor and VSLI Technology. Prior to that, Chan was the chief financial officer and vice-president Finance and Administration at STC Computer Systems and Global Ultimacc Inc.
 Before joining Cygnus, he was controller of Worldwide Operations at LSI Logic Corp., a global designer and manufacturer of advanced high- density integrated circuits (computer chips). Chan's international perspective has deep roots: he was born in Hong Kong, has an L.L.B. from London University, an M.B.A. from Phoenix University, and is a fellow member of the Institute of Chartered Accountants and the Institute of Chartered Secretaries. He has worked on both coasts of the United States and has management experience in both Asian and European operations.
 Cygnus, located in Redwood City, is an innovative developer of transdermal drug delivery systems. Cygnus designed and manufactures the only "waking hours" nicotine patch, sold as Nicotrol(R) in the United States and Canada, and as Nicorette(TM) in Europe. The company has two products in Phase III clinical trials: an estradiol patch to treat menopausal symptoms and osteoporosis, and a fentanyl patch for post-operative pain management.
 The company has over 14 products in development. These include eight female hormone replacement therapy patches and transdermal systems for sedation, analgesia and treatment of angina, anxiety and hypertension. Two consumer products for oral hygiene and cough suppression are in consumer evaluation.
 Cygnus' most exciting new transdermal drug delivery technology is electroporation, which uses pulsed electrical currents to create temporary reversible pathways through cells and tissues. This proprietary technology is particularly promising for delivery of large proteins and peptides, and for non-invasive glucose monitoring.
 -0- 6/10/93
 /CONTACT: Venus Borden of Cygnus, 415-369-4300/
 (CYGN)


CO: Cygnus Therapeutic Systems ST: California IN: MTC SU: PER

TM-SG -- SJ003 -- 4457 06/10/93 13:50 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1993
Words:462
Previous Article:COMERICA BANK-CALIFORNIA EXECUTIVE RETIRES
Next Article:COLUMBIA HOSPITAL CORPORATION AND GALEN HEALTH CARE ANNOUNCE PLANNED MERGER
Topics:


Related Articles
CYGNUS NAMES NEW PRESIDENT AND CEO FORMER CHIRON PRESIDENT JOINS TO LEAD COMMERCIALIZATION
FORMER CITICORP CHAIRMAN AND CEO WALTER WRISTON JOINS CYGNUS BOARD OF DIRECTORS
FRANK CARY, FORMER IBM CHAIRMAN AND CEO, JOINS CYGNUS BOARD OF DIRECTORS
CYGNUS THERAPEUTIC SYSTEMS FILES PUBLIC OFFERING OF 3,000,000 SHARES OF COMMON STOCK
CYGNUS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
CYGNUS ELECTS ANDRE' MARION TO BOARD OF DIRECTORS
P&G TERMINATES MARKETING COLLABORATION WITH CYGNUS FOR SMOKING CESSATION PRODUCTS
Cygnus' Gary Cleary Becomes Chairman Emeritus; John Hodgman to Succeed Dr. Cleary as Chairman of the Board.
Cygnus Business Media Announces Appointment of Carl Fazio As Chief Financial Officer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters